Phylogenetic Analysis of Native Vigna sinensis in Korea Using DNA Sequence of Internal Transcribed spacer (ITS) Region

Pil-Soo Seo(서필수),Sook-Young Lee(이숙영),Yong Kook Shin(신용국) 한국생명과학회 2017 생명과학회지 Vol.27 No.3

본 연구에서 밝혀진 갓끈동부의 ITS1, 5.8S 및 ITS2의 염기서열은 NCBI (National Center for Biotechnology Information)의 GenBank에 Vigna sinensis AY195581로 등록하였다. ITS1, 5.8S 및 ITS2의 총 염기서열 507 염기서열을 이용한 Vigna sinensis (AY195581)의 분자계통분석에서 Vigna unguiculata 및 그 아종들과 98~100% 범위의 염기서열 상동성을 보였다. Vigna unguiculata는 계통분석에 이용된 다른 종들로부터 독립된 하나의 cluster로 그룹핑(grouping)이 됨을 확인하였다. 본 계통분석은 Vigna unguiculata가 Vigna 속의 다른 종에 비해 비교적 최근에 분화되었으며, 현재 유전적인 변화가 많이 일어나고 있음 보이고 있다. 또한, Vigna 속, Vigna longifolia, Vigna vexillata, Vigna membranacea, Vigna friesiorum, Vigna monophylla, Vigna schimperi, Vigna nigritia, Vigna lasiocarpa, Vigna trichocarpa, Vigna diffusa의 다른 종들과 비교하여 유전적으로 독립적인 종임을 확인하였다. 본 연구의 Vigna sinensis의 ITS1, 5.8S 및 ITS2를 이용한 계통분석은 Vigna sinensis를 Vigna unguiculata로 분류하는 것이 타당한 것으로 보여진다. 본 종은 국내에서 멸종된 것으로 알려져 있었으나 최근 토착 식물로써 발견되었고 이 갓끈동부의 관련 식물 종들과의 분자계통학적 위치를 명확히 밝힘에 의의가 있다고 하겠다. Cowpea (Vigna unguiculata (L.) Walp.) is recognized as a potential source of protein and other nutrients. The genus Vigna includes 100 wild species of plants. Especially, Vigna unguiculata includes annual cowpeas (ssp. unguiculata) and ten wild perennial subspecies. DNA sequence of internal transcribed spacer (ITS) region was determined for Vigna sinensis, one of native plant, which was found in recent but thought to have gone extinct in Korea. The seeds of Vigna sinensis used in this study were donated from Dong-Young Jo. The DNA sequence of ITS-5.8S-ITS2 for Vigna sinensis obtained from this study was deposited as Vigna sinensis AY195581 on GenBank of NCBI (National Center for Biotechnology Information). We investigated the sequence-based phylogenetic relationships of plants related and clarified its taxonomical position. DNA similarities among subspecies including Vigna unguiculata showed the range 98 to 100% in sequence-based phylogenetic analysis using total 507 base pairs of ITS1, 5.8S and ITS2. Vigna unguiculata and subspecies were grouped independently as one cluster from other Vigna species used in the phylogenetic analysis. In this study, based on the phylogenetic analysis using the ITS1-5.8S-ITS2 sequence of Vigna sinensis, it may be concluded to be classified to one of Vigna unguiculata substrains.

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis

Soo-Kyung Park,Sang-Bum Kang,Sang Soo Kim,Tae Oh Kim,차재명,Jong Pil Im,Chang Hwan Choi,Eun Soo Kim,Geom Seog Seo,Chang Soo Eun,Dong Soo Han,Dong Il Park 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.5

Background/Aims: In ulcerative colitis (UC) patients, Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, evidence of the ability of EcN to increase health-related quality of life or induce remission remains scarce. We investigated the efficacy of EcN as an add-on therapy for UC. Methods: In this multicentre, double-blind, randomised, placebo-controlled study, a total of 133 UC patients were randomly assigned to receive either EcN or placebo once daily for 8 weeks. Inflammatory bowel disease questionnaire (IBDQ) scores (primary endpoint) and clinical remission and response rates (secondary endpoints) were compared (Clinical trial registration number: NCT04969679). Results: In total, 118 patients (EcN, 58; placebo, 60) completed the study. The number of patients reaching the primary endpoint did not differ between the EcN and placebo groups (30 [51.7%] vs. 31 [51.7%]; per-protocol analysis, p = 1.0; intention- to-treat analysis, p = 0.86). However, significantly fewer patients in the EcN group exhibited a decreased IBDQ score (1 [1.7%] vs. 8 [13.3%]; per-protocol analysis, p = 0.03; intention-to-treat analysis, p = 0.02). Moreover, a significantly higher number of patients in the EcN group displayed clinical response at 4 weeks (23 [39.7%] vs. 13 [21.7%], p = 0.04) and endoscopic remission at 8 weeks (26 [46.4%] vs. 16 [27.1%], p = 0.03). Conclusions: Although the number of patients reaching the primary endpoint did not differ between the EcN and placebo groups, EcN was found to be safe and effective in preventing the exacerbation of IBDQ scores and achieving clinical responses and endoscopic remission in patients with mild-to-moderate UC.

Bacterial Expression and Purification of Human Papillomavirus Type 18 L1

Pil-Soo Seo,Sun-Yeon Heo,Eun Jong Han,서정우,Shin-Je Ghim,Chul Ho Kim 한국생물공학회 2009 Biotechnology and Bioprocess Engineering Vol.14 No.2

The human papillomavirus (HPV) 18 L1 gene, which encodes the L1 major capsid protein, was isolated from a female patient in Pusan, Korea Republic and was cloned into pGEX-4T-1 vector. The HPV-18L1 gene was expressed in Escherichia coli as a fusion protein with a glutathione-S-transferase (GST) tag. The soluble recombinant fusion protein, GST-18 L1 fusion, was isolated to high purity. HPV-18 L1 was purified from the GST-18 L1 fusant after biotinylated thrombin cleavage, and then the treated thrombin was removed serially using streptavidin conjugated resin. The purified HPV-18 L1 was confirmed by western blotting using a rabbit anti-denatured papillomavirus polyclonal antibody. The virus-like particles (VLP) from the purified full-length 18 L1 protein without any extra amino acid sequences was observed through the analysis of the electron microscope. This is the first study to report the expression and purification of HPV-18 L1 in E.coli. This expression and purification system offers a simple method of expressing and purifying HPV L1 protein, and could potentially be an effective route for the development and manufacturing of highly purified HPV-18 L1-based cervical cancer vaccines The human papillomavirus (HPV) 18 L1 gene, which encodes the L1 major capsid protein, was isolated from a female patient in Pusan, Korea Republic and was cloned into pGEX-4T-1 vector. The HPV-18L1 gene was expressed in Escherichia coli as a fusion protein with a glutathione-S-transferase (GST) tag. The soluble recombinant fusion protein, GST-18 L1 fusion, was isolated to high purity. HPV-18 L1 was purified from the GST-18 L1 fusant after biotinylated thrombin cleavage, and then the treated thrombin was removed serially using streptavidin conjugated resin. The purified HPV-18 L1 was confirmed by western blotting using a rabbit anti-denatured papillomavirus polyclonal antibody. The virus-like particles (VLP) from the purified full-length 18 L1 protein without any extra amino acid sequences was observed through the analysis of the electron microscope. This is the first study to report the expression and purification of HPV-18 L1 in E.coli. This expression and purification system offers a simple method of expressing and purifying HPV L1 protein, and could potentially be an effective route for the development and manufacturing of highly purified HPV-18 L1-based cervical cancer vaccines

적조 와편모조류 , Cochlodinium polykrikoides 의 순수분리 및 성장

서필수(Pil Soo Seo),이상준(Sang Jun Lee),김윤(Yoon Kim),이정호(Jeong Ho Lee),김학균(Hak Gyoon Kim),이재동(Jae Dong Lee) 한국수산과학회 1998 한국수산과학회지 Vol.31 No.1

To know the antibiotic specificity of a dinoflagellate, Cochlodinium polykrikoides, we investigated the survival time of C. polykrikoides against several concentrations of antibiotics and judged the selective specificity of antibiotics based on the LT_(50)(50% of lethal time). The result showed that C. polykrikoides was sensitive to tetracycline and chloramphenicol, and resistant to polymixin-B, ampicillin, penicillin-G, dihydrostreptomycin, and neomycin. In the case of sensitive antibiotics to C. polykrikoides, tetracycline and chloramphenicol, the safety concentrations of both antibiotics were determined and the antibiotic specificity based on the plotted survival curve was analyzed. Before antibiotic treatment, we tested the antibiotic susceptibility of the contaminated bacterial population in the culture of C. polykrikoides, and decided the proper kinds of antibiotics and concentrations before percoll-centrifugation. By percoll-centrifugation, we reduced bacteria, removed fungi, collected the algal pellet, and made axenic culture by antibiotic cascade procedure based on the result of antibiotic susceptibility test. We observed that axenic C. polykrikoides culture entered the logarthmic phase of growth when cell density was over 740cells/㎖ and propagated to 5,800cells/㎖ maximally. Divisions per day, k value of C polykrikoides represented a good index for growth at the low density of cells. There was a highest k value shift before reaching to the logarithmic phase. We suggested that the preceeding highest k value shift stage is a good indicator for accurate broadcasting for red tide blooming in the field, and the stage is also a good time for controlling red tide blooming in the field, either.

Engineering Klebsiella Pneumoniae to Eliminate By-Products Formation during Production of 1,3-Propanediol from Glycerol

Jeong-Woo SEO,Mi-Young SEO,Baek-Rock OH,Sun-Yeon HEO,Jin-Oh BAEK,Pil-Soo SEO,Min Ho CHOI,Chul Ho KIM 한국생물공학회 2009 한국생물공학회 학술대회 Vol.2009 No.4

Elimination of By-Products Formation during Production of 1,3-Propanediol from Glycerol in Klebsiella Pneumoniae by Inactivation of the Oxidative Pathway for Glycerol Metabolism

Mi-Young SEO,Jeong-Woo SEO,Sun-Yeon HEO,Jin-Oh BAEK,Dina RAIRAKHWADA,Baek-Rock OH,Pil-Soo SEO,Min Ho CHOI,Chul Ho KIM 한국생물공학회 2009 한국생물공학회 학술대회 Vol.2009 No.4

First records of Paratymolus pubescens Miers, 1879 and Litosus sexspinosus (Miers, 1884) (Decapoda, Brachyura, Inachidae) from Korean waters

Seo, In-Soo,Kim, Mi Hyang,Hwang, Un-Ki,Yoon, Sang-Pil BRILL ACADEMIC PUBLICATIONS 2017 Crustaceana Vol.90 No.6

Effect of nitrogen sources on molecular weight and production of exopolymer by Aureobasidum pullulans

Seo,Hyung Pil,Kim,Mi Ryung,Kim,Sung Koo,Cho,Young Soo,Chung,Chung Han,Lee,Jin Woo 한국생명과학회 2000 한국생명과학회 학술발표회 Vol.27 No.-

Effect of byproduct from production process for soybean source as the nitrogen source on production of extracellular polysaccharides by Aureobasidum pullulans HP- 2001 was investigated. The byproduct from production process for soybean source were found to be good nitrogen sources. The conversion rate of 2% (w/v) glucose to exopolymer with this nitrogen source was about 50%. Molecular weight of exopolymers also affected by nitrogen sources.

Risk Factors for Mortality in Patients with Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae and Escherichia coli bacteremia

Seo Hyeonji,Bae Seongman,Kim Min-Jae,Chong Yong Pil,Kim Sung-Han,Lee Sang-Oh,Choi Sang-Ho,Kim Yang Soo,Jung Jiwon 대한감염학회 2021 Infection and Chemotherapy Vol.53 No.3

Background: Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales bacteremia is associated with significant mortality; however, no optimal antibiotic strategy is available. We aimed to evaluate the clinical outcomes according to the antibiotic regimens and identify risk factors for mortality in patients with KPC-producing K. pneumoniae and Escherichia coli bacteremia. Materials and Methods: This retrospective cohort study included all adult patients with monomicrobial bacteremia (KPC-producing K. pneumoniae or E. coli) between January 2011 and March 2021 at a 2,700-bed tertiary center. Results: Ninety-two patients were identified; 7 with E. coli bacteremia, and 85 with K. pneumoniae bacteremia. Thirty-day mortality was 38.0% (35/92). Non-survivors were more likely to have had nosocomial infection (88.6% vs. 63.2%, P = 0.01), high APACHE II scores (mean [interquartile range], 22.0 [14.0 - 28.0] vs. 14.0 [11.0 - 20.5], P <0.001), and septic shock (51.4% vs. 26.3%, P <0.001) and less likely to have been admitted to the surgical ward (5.7% vs. 22.8%, P = 0.04), undergone removal of eradicable foci (61.5% vs. 90.6%, P = 0.03), and received appropriate combination treatment (57.1% vs. 78.9%, P = 0.03) than survivors. No significant difference in mortality was observed according to combination regimens including colistin, aminoglycoside, and tigecycline. In multivariable analysis, high APACHE II scores (adjusted odds ratio [aOR], 1.14; 95% confidence interval [CI], 1.06 - 1.23, P <0.001), and appropriate definitive treatment (aOR, 0.25; CI, 0.08 - 0.74, P = 0.01) were independent risk factors for mortality. Conclusion: High APACHE II scores and not receiving appropriate definitive treatment were associated with 30-day mortality. Mortality did not significantly differ according to combination regimens with conventional drugs such as aminoglycoside and colistin.

Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial

Seo Hyeonji,Kim Haein,Bae Seongman,Park Seonghee,Chung Hyemin,Sung Heungsup,Jung Jiwon,Kim Min-Jae,Kim Sung-Han,Lee Sang-Oh,Choi Sang-Ho,Kim Yang Soo,Son Ki Young,Chong Yong Pil 대한감염학회 2022 Infection and Chemotherapy Vol.54 No.1

Background This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and Methods A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real time-polymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 - 60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group (P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo (ClinicalTrials.gov Identifier: NCT04711863). Background This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and Methods A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real time-polymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 - 60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group (P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo (ClinicalTrials.gov Identifier: NCT04711863).